JATT Acquisition (NYSE:JATT – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 1.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares JATT Acquisition and Editas Medicine”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
Editas Medicine | $78.12 million | 1.33 | -$153.22 million | ($2.56) | -0.49 |
Analyst Ratings
This is a summary of recent ratings for JATT Acquisition and Editas Medicine, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
JATT Acquisition | 0 | 0 | 0 | 0 | 0.00 |
Editas Medicine | 2 | 9 | 3 | 0 | 2.07 |
Editas Medicine has a consensus price target of $7.00, indicating a potential upside of 455.56%. Given Editas Medicine’s stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than JATT Acquisition.
Profitability
This table compares JATT Acquisition and Editas Medicine’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
JATT Acquisition | N/A | -49.58% | 2.84% |
Editas Medicine | -340.96% | -80.13% | -50.99% |
About JATT Acquisition
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for JATT Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JATT Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.